Holen Sie sich die Stockscreener-App
123.78
0.05%
0.0617
Schlusskurs vom Vortag:
$123.72
Offen:
$123.71
24-Stunden-Volumen:
546.64K
Relative Volume:
0.26
Marktkapitalisierung:
$9.79B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-450.07M
KGV:
-20.43
EPS:
-6.0583
Netto-Cashflow:
$-312.79M
1W Leistung:
+0.23%
1M Leistung:
+36.10%
6M Leistung:
+15.88%
1J Leistung:
+58.84%
1-Tages-Spanne:
$123.71
$123.83
1-Wochen-Bereich:
$123.50
$123.83
52-Wochen-Spanne:
$71.13
$123.83
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
123.78 | 9.79B | 0 | -450.07M | -312.79M | -6.0583 |
VRTX
Vertex Pharmaceuticals Inc
|
523.88 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.87 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.67 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.22 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.59 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Nuvalent chief development officer Noci sells $2.84m in stock - Investing.com
Form 4 Nuvalent Inc For: 6 July By Investing.com - Investing.com Canada
Nuvalent (NUVL) CDO exercises options and sells 23,000 shares - Stock Titan
Nuvalent (NUVL) CFO sells 11,430 shares and exercises options under plan - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
GSK acquires Nuvalent for $10.6 billion in oncology push - qz.com
Enterprise value to revenue forward of Nuvalent, Inc. – NASDAQ:NUVL - TradingView
Nuvalent Inc stock hits all-time high at 123.7 USD - Investing.com
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders - GlobeNewswire
NUVL (NASDAQ: NUVL) Form 144 lists insider sale of Class A Common - Stock Titan
Insider at Nuvalent (NUVL) exercises options and sells 5,500 shares - Stock Titan
GSK agrees to acquire Nuvalent, Inc. - Pennsylvania Business Report -
Halper Sadeh LLC is Investigating Whether LCII, NUVL, DAN, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Halper Sadeh LLC is Investigating Whether LCII, NUVL, DAN, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSETMH - GlobeNewswire
GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share - Yahoo Finance
GSK ends £2bn buyback with shares near 2,000p; Nuvalent deal in focus - Bez Kabli
NUVL News | NUVALENT INC-A (NASDAQ:NUVL) - ChartMill
GSK trades close to analyst target after Nuvalent deal - Bez Kabli
Nuvalent, Inc.(NasdaqGS: NUVL) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Nuvalent, Inc.(NasdaqGS: NUVL) added to Russell 2000 Defensive Index - marketscreener.com
(NUVL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
GSK plc (LON:GSK) share price: 3% weekly gain puts Nuvalent tender deadline in view - Bez Kabli
GSK launches $124-a-share takeover bid for cancer biotech Nuvalent - Indian Pharma Post
GSK announces Nuvalent tender offer, shares supported by oncology push - Ad-hoc-news.de
Enterprise value to EBIT forward of Nuvalent, Inc. – NASDAQ:NUVL - TradingView
Price to sales forward of Nuvalent, Inc. – NASDAQ:NUVL - TradingView
Nuvalent, Inc. Class A Actuals & Estimates (NASDAQ:NUVL) - TradingView
Price to book forward of Nuvalent, Inc. – NASDAQ:NUVL - TradingView
Price to earnings forward of Nuvalent, Inc. Class A – FWB:5AX - TradingView
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? - TradingView
NUVL Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Nuvalent, Inc. Class A – FWB:5AX - TradingView
Enterprise value to revenue forward of Nuvalent, Inc. Class A – FWB:5AX - TradingView
Price to sales forward of Nuvalent, Inc. Class A – FWB:5AX - TradingView
GSK shares unchanged as Nuvalent guidance puts pressure on $10.6 billion buyout - Bez Kabli
Enterprise value to EBITDA forward of Nuvalent, Inc. Class A – FWB:5AX - TradingView
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, NUVL, AXTA, and PFLC - Sahm
Key facts: GSK $124 offer for Nuvalent; HIV shifts to injectables - TradingView
GSK commences tender offer for Nuvalent shares - MLex
GSK (NUVL) bidders launch $124.00 cash tender for Nuvalent shares - Stock Titan
GSK announces commencement of tender offer to acquire Nuvalent, Inc. - GSK
GSK Unit Launches Tender Offer for Nuvalent Acquisition - Moomoo
GSK Initiates Tender Offer for Nuvalent Shares - GuruFocus
GSK commences tender offer to acquire Nuvalent for $124 per share - Investing.com
NUVL Downgraded by Bernstein -- Price Target Lowered to $124 - GuruFocus
GSK launches tender offer for USD10.6 billion purchase of Nuvalent - London South East
GSK (NYSE: GSK) moves to acquire Nuvalent with $124/share cash tender offer - Stock Titan
GSK commences tender offer to acquire Nuvalent for $124 per share By Investing.com - Investing.com India
GSK, Nuvalent to submit premerger notification - MLex
Bernstein analysts have made a significant adjustment to their rating on Nuvalent, Inc., downgrading it from "Outperform" to "Market Perform." - Bitget
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvalent Inc-Aktie (NUVL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Jul 01 '26 |
Sale |
123.59 |
23,000 |
2,842,570 |
58,117 |
| Balcom Alexandra | Chief Financial Officer |
Jul 01 '26 |
Option Exercise |
13.26 |
11,430 |
151,547 |
96,963 |
| Balcom Alexandra | Chief Financial Officer |
Jul 01 '26 |
Sale |
123.58 |
11,430 |
1,412,519 |
85,533 |
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):